Substituted pyridine spleen tyrosine kinase (SYK) inhibitors

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Merck Sharp & Dohme Corp., , Merck Canada Inc. patent solves the following problem:

Spleen Tyrosine Kinase (SYK) is a protein tyrosine kinase described as a key mediator of immunoreceptor signaling a host of inflammatory cells including mast cells, B-cells, macrophages and neutrophils. These immunoreceptors, including Fc receptor and the B-cell receptor, is important for allergic diseases, and antibody-mediated autoimmune diseases and thus pharmacologically interfering SYK conceivably treat these diseases.

Our analysis of this patent is as follows:

Merck Sharp & Dohme Corp., , Merck Canada Inc.’s patent US 9376418 B2 deals with Substituted pyridine spleen tyrosine kinase (SYK) inhibitors.
invention provides certain substituted Pyridines of Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, P3, R4, rcy, CY, and t as described here. invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated spleen tyrosine kinase (SYK) kinase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Aerodynamic device for the rear of a trailer

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Trailstar International, Inc. patent solves the following problem:

The present invention relates generally to the field of aerodynamic devices to reduce drag. Particularly, the present invention relates to a flying device adapted to extend from the back of a trailer or semi-trailer container. In particular, the present invention relates to an air intake scoop and an inflatable member extending outwardly from a trailer.

Our analysis of this patent is as follows:

Trailstar International, Inc.’s patent US 9371097 B1 deals with Aerodynamic device for the rear of a trailer.
A flying device for a trailer includes an inflatable member with a back wall of a trailer adapted to inflate its rearwardly to reduce drag as the trailer pulled forwardly. The flying device further includes an air intake scoop mounted under the rear wall of the trailer in fluid communication with inflatable member filling the inflatable member in the air as the trailer moves forward.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Dmv-Fonterra Excipients Technology Gmbh, , Glaxo Group Limited patent solves the following problem:

In the field of inhalation therapy, it is generally desirable to use therapeutic molecules having a particle size (ie, diameter) in the range of 1 to 10 m. carrier molecule or excipients, such as lactose, canine therapeutic preparation also includes significantly larger diameter particles (for example, 100 to 150 m) which are not normally penetrate into the upper respiratory tract to the same degree as the active ingredient. In general, it is better to use a smaller particle size for the lactose or a lactose blend having a defined ratio of coarse and fine lactose.

Our analysis of this patent is as follows:

Dmv-Fonterra Excipients Technology Gmbh, , Glaxo Group Limited’s patent US 9365905 B2 deals with Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom.
A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w / w of lactose particles with a number average the particle size of about 70 microns or less; stands the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), from 50 micron to 100 micron; and classifying the plurality of milled lactose particles at least two pieces consisting of a fine particle and a coarse particle in which the fine particle has an average particle size, (D50), from 3 microns to 50 microns, and the coarse particle has an average particle size, (D50), from 40 micron to 250 micron.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.